Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Infectious Disease Clinics of North America · 2024-03 · 38 (1) · 149-162
DOI: 10.1016/j.idc.2023.12.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infectious Disease Clinics of North America, 2024-03. Verfasst von Thomas S Murray und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Section Infectious Diseases and Global Health, Yale University School of Medicine, PO Box 208064, 333 Cedar Street, New Hav…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Methicillin-Resistant Staphylococcus aureus, Stenotrophomonas maltophilia, Respiratory Tract Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Yale University.
Abstract (Originalsprache)
Patients with cystic fibrosis (CF) often develop respiratory tract infections with pathogenic multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus, and a variety of gram-negative organisms that include Pseudomonas aeruginosa, Burkholderia sp., Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and nontuberculous mycobacteria (NTM). Despite the introduction of new therapies to address underlying cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, MDRO infections remain a problem and novel antimicrobial interventions are still needed. Therapeutic approaches include improving the efficacy of existing drugs by adjusting the dose based on differences in CF patient pharmacokinetics/pharmacodynamics, the development of inhaled formulations to reduce systemic adverse events, and the use of newer beta-lactam/beta-lactamase combinations. Alternative innovative therapeutic approaches include the use of gallium and bacteriophages to treat MDRO pulmonary infections including those with extreme antibiotic resistance. However, additional clinical trials are required to determine the optimal dosing and efficacy of these different strategies and to identify patients with CF most likely to benefit from these new treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Section Infectious Diseases and Global Health, Yale University School of Medicine, PO Box 208064, 333 Cedar Street, New Haven, CT 06520-8064, USA. Electronic address: Thomas.s.murray@yale.edu.
- Department of Internal Medicine, Section Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, PO Box 208057, 300 Cedar Street TAC-441 South, New Haven, CT 06520-8057, USA; Adult Cystic Fibros…
- Adult Cystic Fibrosis Program; Yale University Center for Phage Biology & Therapy; Department of Internal Medicine, Section Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, PO Box 208057,…
Förderung
- Yale University
Zitieren
APA
Murray, T. S., Stanley, G., & Koff, J. L. (2024). Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Infectious Disease Clinics of North America, 38(1), 149-162. https://doi.org/10.1016/j.idc.2023.12.002
Vancouver
Murray TS, Stanley G, Koff JL. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Infectious Disease Clinics of North America. 2024;38(1):149-162. doi:10.1016/j.idc.2023.12.002
BibTeX
@article{Murray2024,
author = {Murray, Thomas S and Stanley, Gail and Koff, Jonathan L},
title = {Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis},
journal = {Infectious Disease Clinics of North America},
year = {2024},
volume = {38},
number = {1},
pages = {149--162},
doi = {10.1016/j.idc.2023.12.002}
}
EUVIMED